Bellicum Pharmaceuticals Overview

  • Founded
  • 2004

Founded
  • Status
  • Public

  • Employees
  • 7

Employees
  • Stock Symbol
  • BLCM

Stock Symbol
  • Share Price
  • $1.10

  • (As of Wednesday Closing)

Bellicum Pharmaceuticals General Information

Description

Bellicum Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. Its research areas are cellular immunotherapies for hematological cancers, solid tumors, and orphan inherited blood diseases. The company's expertise is based on the inclusion of powerful molecular switches planned to eliminate, reduce, or activate therapeutic cells to increase efficacy and safety compared with existing cell therapies. Its pipeline portfolio includes adjunct T-cell therapy to treat leukemias, lymphomas, and genetic blood diseases; CAR T cells technology to treat prostate, pancreatic, bladder, esophagus, and gastric cancers; and BCMA GoCAR-NK the program targeting B-cell maturation antigen.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Stock Exchange
NAS
Primary Office
  • 3730 Kirby Drive
  • Suite 1200
  • Houston, TX 77098
  • United States
+1 (281) 000-0000

Bellicum Pharmaceuticals Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Bellicum Pharmaceuticals Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.10 $1.10 $1.00 - $3.00 $9.5M 8.61M 21.1K -$0.18

Bellicum Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 30-Jun-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV (11,488) 11,283 18,768 27,231
Revenue 5,500 6,200 500 7,143
EBITDA (7,797) (9,595) (3,576) (101,042)
Net Income (7,799) (9,705) (7,722) (112,477)
Total Assets 36,604 49,143 40,584 116,250
Total Debt 0 0 1,169 38,035
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Bellicum Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Bellicum Pharmaceuticals‘s full profile, request access.

Request a free trial

Bellicum Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Bellicum Pharmaceuticals‘s full profile, request access.

Request a free trial

Bellicum Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Bellicum Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. Its research areas are cellular immunotherap
Drug Discovery
Houston, TX
7 As of 2021
00000
000000000 00000

0000 0

lore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliqui
0000 000000000
Cambridge, MA
00 As of 0000
00000
00000000 00000

00000

psum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolo
0000000000000
Waltham, MA
000 As of 0000
00000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Bellicum Pharmaceuticals Competitors (52)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aura Biosciences Formerly VC-backed Cambridge, MA 00 00000 00000000 00000
00000 000000000000 Formerly VC-backed Waltham, MA 000 00000 00000000 00000
0000 000000000000 Formerly VC-backed Houston, TX 00 00000 000000&0 00000
0000000 Venture Capital-Backed Philadelphia, PA 00 00000 00000000000 00000
0000000 0000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
You’re viewing 5 of 52 competitors. Get the full list »

Bellicum Pharmaceuticals Patents

Bellicum Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020327994-A1 Improved formulations for immune cells Pending 12-Aug-2019 000000000
EP-4013513-A1 Improved formulations for immune cells Pending 12-Aug-2019 000000000
CA-3147289-A1 Improved formulations for immune cells Pending 12-Aug-2019 000000000
US-20220273717-A1 Improved formulations for immune cells Pending 12-Aug-2019 0000000000
AU-2019397048-A1 Psca car-t cells Pending 13-Dec-2018 A61K35/17
To view Bellicum Pharmaceuticals’s complete patent history, request access »

Bellicum Pharmaceuticals Executive Team (17)

Name Title Board Seat Contact Info
Richard Fair Chief Executive Officer & Board Member
Charity Scripture Executive
You’re viewing 2 of 17 executive team members. Get the full list »

Bellicum Pharmaceuticals Board Members (11)

Name Representing Role Since
James Daly Self Board Member 000 0000
Jon Stonehouse Self Chairman & Board Member 000 0000
Judith Klimovsky Self Board Member 000 0000
Reid Huber Ph.D Self Board Member 000 0000
Richard Fair Bellicum Pharmaceuticals Chief Executive Officer & Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Bellicum Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial